According to Enzo Biochem's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0.978635. At the end of 2023 the company had a P/S ratio of 1.77.
Year | P/S ratio | Change |
---|---|---|
2023 | 1.77 | 67.73% |
2022 | 1.05 | -26.86% |
2021 | 1.44 | 39.78% |
2020 | 1.03 | -44.98% |
2019 | 1.88 | 17.68% |
2018 | 1.59 | -62.33% |
2017 | 4.23 | 55.72% |
2016 | 2.72 | 55.35% |
2015 | 1.75 | -27.63% |
2014 | 2.42 | 116.86% |
2013 | 1.11 | 46.1% |
2012 | 0.7630 | -29.41% |
2011 | 1.08 | -35.88% |
2010 | 1.69 | -24.3% |
2009 | 2.23 | -18.02% |
2008 | 2.72 | -62.74% |
2007 | 7.29 | -36.68% |
2006 | 11.5 | 13.43% |
2005 | 10.1 | -26.26% |
2004 | 13.8 | 11.74% |
2003 | 12.3 | 74.3% |
2002 | 7.07 | -24.46% |
2001 | 9.35 |
Company | P/S ratio | P/S ratio differencediff. | Country |
---|---|---|---|
![]() Quest Diagnostics
DGX | 1.47 | 50.25% | ๐บ๐ธ USA |
![]() LabCorp LH | 1.31 | 33.90% | ๐บ๐ธ USA |
![]() RadNet RDNT | 1.25 | 27.93% | ๐บ๐ธ USA |
![]() Psychemedics PMD | 0.8949 | -8.56% | ๐บ๐ธ USA |
![]() NeoGenomics
NEO | 2.86 | 192.04% | ๐บ๐ธ USA |
![]() Qiagen QGEN | 4.51 | 361.29% | ๐ณ๐ฑ Netherlands |